?

Log in

No account? Create an account

<ранешнее | следущее>


Внимательно читал, много думал ...

Found 6 studies with search of: hcv | Open Studies | Russian Federation
RankStatusStudy
1RecruitingA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
Condition:Hepatitis C, Chronic
Intervention:Drug: peginterferon alfa-2a [Pegasys]
Sponsor:Hoffmann-La Roche
Gender:Both
Group:Adult
Phase:Phase IV
Number Enrolled:150
Funded By:INDUSTRY
Study Design:Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
NCT ID:NCT00474955
Other IDs:ML20434
Start Date:July 2007
Completion Date:December 2012
Last Updated Date:May 25, 2010
Primary Completion Date: 
Outcome Measures:Percentage of patients with SVR;   Percentage of patients with undetectable HCV-RNA;   Percentage of patients with a 2log10 drop in HCV-RNA;   SAEs, premature withdrawals, AEs and laboratory parameters.
2RecruitingA Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
Condition:Hepatitis C, Chronic
Interventions:Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin
Sponsor:Hoffmann-La Roche
Gender:Both
Age Groups:Adult / Senior
Phase:Phase IV
Number Enrolled:6000
Funded By:INDUSTRY
Study Design:Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
NCT ID:NCT00922779
Other IDs:ML16709
Start Date:June 2002
Completion Date:August 2011
Last Updated Date:May 25, 2010
Primary Completion Date: 
Outcome Measures:Adverse events; laboratory parameters;   Sustained viral response

 
3RecruitingA Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK7009)
Condition:Hepatitis C
Intervention:Drug: vaniprevir (MK7009)
Sponsor:Merck
Gender:Both
Group:Adult
Phase:Phase I
Number Enrolled:60
Funded By:INDUSTRY
Study Design:Allocation: Randomized;   Control: Active Control;   Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
NCT ID:NCT01010906
Other IDs:2009_674,   MK7009-005
Start Date:July 2009
Completion Date:May 2010
Last Updated Date:April 13, 2010
Primary Completion Date:May 2010
Outcome Measure:AUC(0-infinity) of vaniprevir following single dose administration

 
4RecruitingEfficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
Condition:Liver Transplantation
Interventions:Drug: Everolimus;   Drug: Tacrolimus
Sponsor:Novartis
Gender:Both
Age Groups:Adult / Senior
Phase:Phase III
Number Enrolled:690
Funded By:INDUSTRY
Study Design:Allocation: Randomized;   Control: Active Control;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
NCT ID:NCT00622869
Other IDs:CRAD001H2304
Start Date:January 2008
Completion Date: 
Last Updated Date:November 19, 2009
Primary Completion Date:January 2010
Outcome Measures:Assessment of renal function by Estimated Glomerular Filtration Rate,eGFR , using abbreviated Modification of Diet in Renal Disease at 12-mths post-transplantation Composite efficacy failure of death,graft loss,or loss to follow-up at 12-mths post-trans.;   Composite efficacy endpoint of treated biopsy proven acute rejection, graft loss, death or loss to follow-up at 12&24 mths post-transp.Incidence onset diabetes post-transp.
5RecruitingLENS - Long-term Eltrombopag Observational Study
Condition:Ocular Safety
Intervention:Drug: Observational Study
Sponsor:GlaxoSmithKline
Gender:Both
Age Groups:Child / Adult / Senior
Phase: 
Number Enrolled:350
Funded By:INDUSTRY
Study Design:Observational Model: Cohort;   Time Perspective: Prospective
NCT ID:NCT00643929
Other IDs:TRA108132
Start Date:February 2007
Completion Date:April 2013
Last Updated Date:June 3, 2010
Primary Completion Date:April 2013
Outcome Measures:Description of the incidence of changes in lens over time;   Exploratory epidemiologic analyses of ocular data from patients previously enrolled in studies with eltrombopag.

 
6RecruitingClinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura
Condition:Idiopathic Thrombocytopenic Purpura
Intervention:Biological: IGIV3I Grifols
Sponsor:Grifols Biologicals Inc.
Gender:Both
Age Groups:Adult / Senior
Phase:Phase III
Number Enrolled:20
Funded By:INDUSTRY
Study Design:Control: Uncontrolled;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
NCT ID:NCT00699140
Other IDs:IG-202
Start Date:February 2008
Completion Date:September 2010
Last Updated Date:March 15, 2010
Primary Completion Date:September 2010
Outcome Measures:Increase of platelet count >/= 50,000/µl and regression of bleeding episodes.;   Changes in vital signs and clinically relevant changes in laboratory parameters after the infusions, including renal function (creatinine levels);   Viral safety through the investigation of patients virology status (HAV, HBV, HCV and HIV) and assessment of alteration in their liver function;   Nature, severity and frequency of adverse reactions during and after infusions;   Frequency of responders (platelet count >/= 50,000/µl;   Time to reach platelet count >/= 50,000/µl;   Length of time platelet count remains ./= 50,000/µl.;   Regression of hemorrhages.

 





Житие инфицированного вирусным гепатитом

Comments

( 1 комментарий — Комментируй )
(Удалённый комментарий)
hcv_infected_ru
2 сент, 2010 01:18 (UTC)
И что ж Вам мешает)
( 1 комментарий — Комментируй )

Последний месяц

Июль 2010
Вс Пн Вт Ср Чт Пт Сб
    123
45678910
11121314151617
18192021222324
25262728293031
Разработано LiveJournal.com
Designed by Lilia Ahner